Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “CYSTAMINE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,099 records · Page 61Linked to original sources
PubMed1982

Inhibition of adrenaline-induced platelet aggregation by the alpha-adrenoceptor blocking drug benextramine.

1 The activity of the irreversible alpha-adrenoceptor blocking drug, benextramine, was determined in human platelets. 2 Compared to its postsynaptic and presynaptic alpha-adrenoceptor blocking potency, benextramine had a very low potency as an antagonist of adrenaline-induced platelet aggregation. 3 The results confirm the previous observation with the irreversible alpha-adrenoceptor blocking drug, phenoxybenzamine, that platelet alpha-adrenoceptors differ from postsynaptic and presynaptic alpha-adrenoceptors.

Adenosine Diphosphate↗
PubMed1983

Demonstration of alpha 1s-adrenoceptors after exposure of the rat anococcygeus to benextramine.

Sgd 101/75 (4(2-imidazoline-amino)-2-methylindazol-chlorhydrate) and noradrenaline exerted similar, full agonist effects on the alpha-adrenoceptors of the rat anococcygeus. Benextramine (30 microM for 30 min, followed by 20 washes over 30 min) abolished contractions of the anococcygeus to Sgd 101/75, but only reduced those to noradrenaline. Sgd 101/75 (400 microM) did not significantly reduce contractions of the benextramine-treated (30 microM) anococcygeus to noradrenaline. It is concluded that benextramine can replace phenoxybenzamine as the alkylating agent in the demonstration of alpha 1s-adrenoceptors in the rat anococcygeus.

Adrenergic alpha-Antagonists↗
PubMed1987

Lack of involvement of alpha-adrenoceptors in sympathetic neural vasoconstriction in the hindquarters of the rabbit.

The hypothesis that sympathetic nerves in arterial blood vessels activate excitatory receptors distinct from alpha-adrenoceptors was investigated in vivo in the rabbit. In anaesthetized, ganglion-blocked rabbits, graded stimulation of the lumbar sympathetic nerve chains caused graded hind limb vasoconstriction. The responses to single pulses and short trains of stimuli were unaffected by benextramine (10 mg kg-1) and the longer trains were enhanced. Phenoxybenzamine (5 mg kg-1) slightly reduced the responses to short trains of stimuli and did not affect the responses to long trains. The dose-response curve to intra-arterial noradrenaline (after beta-adrenoceptor blockade) was shifted rightwards about ten fold by benextramine (10 mg kg-1) and by phenoxybenzamine (5 mg kg-1). In conscious rabbits the vasoconstriction caused by the nasopharyngeal reflex initiated by smoke inhalation was unaffected by benextramine (10 mg kg-1). Small mesenteric arteries (less than 250 microns) taken from untreated rabbits responded to noradrenaline with a threshold concentration of about 1 microM. Similar tissues from benextramine (10 mg kg-1)-treated rabbits were unresponsive to noradrenaline at concentrations up to 300 microM. However, these tissues were able to respond to potassium and angiotensin II. Aortic ring segments taken from the same rabbits were only about ten fold less sensitive to noradrenaline than segments from control rabbits. These results are in accord with the hypothesis that sympathetic nerves activate non-alpha-receptors in the vasculature of the rabbit.

Adrenergic alpha-Antagonists↗
PubMed1989

Characterization of pigment aggregating alpha 2-adrenoceptors of fish melanophores by use of different agonists after partial irreversible receptor inactivation.

1. The affinity for, and the intrinsic efficacy on, postsynaptic melanosome aggregating alpha 2-adrenoceptors of fish melanophores was studied for B-HT 920, clonidine, medetomidine, noradrenaline, phenylephrine and UK-14,304. Investigations were carried out by evaluating the effects of progressive, irreversible inactivation of the alpha 2-adrenoceptors by benextramine. 2. The double reciprocal plots of equieffective concentrations of B-HT 920, clonidine, noradrenaline and phenylephrine were linear, which indicated that these compounds exerted their effects, mainly, through interaction with one receptor site. 3. The affinity for the alpha 2-adrenoceptor selective agonist B-HT 920, was found to be about 1000 times higher than the affinity for the alpha 1-adrenoceptor selective agonist phenylephrine. 4. The corresponding plot of equieffective concentrations of medetomidine was not linear, which may indicate that this imidazole compound exerted its effect through more than one receptor site. However, when phenoxybenzamine was used in place of the more selective benextramine, a linear relationship was obtained.

Adrenergic alpha-Agonists↗
PubMed1995

Failure of the putative neuropeptide Y antagonists, benextramine and PYX-2, to inhibit Y2 receptors in rat isolated prostatic vas deferens.

1. The pharmacological activity of neuropeptide Y (NPY) and some analogues in inhibiting the twitch contractions induced by electrical stimulation (single pulses at 25 V, 0.15 Hz, 1 ms) in the prostatic portion of the rat isolated vas deferens was investigated. The rank order of agonist potency was: PYY > NPY2-36 > NPY >> NPY13-36 >> NPY18-36 >> [Leu31,Pro34]NPY = hPP, which is consistent with the activation of a Y2 receptor. 2. The putative Y1 and Y2 antagonist, benextramine (BXT), incubated at 100 microM for 10 or 60 min, was ineffective against PYY-induced inhibition of the twitch response, suggesting that the prejunctional Y2 receptor in this tissue is different from the postjunctional one reported in the literature to be sensitive to BXT blockade. 3. The putative NPY antagonist, PYX-2, incubated at 1 microM for 20 min, was completely ineffective in antagonizing PYY-induced inhibition of twitches. 4. The twitch response was totally inhibited by suramin (100 microM) but was little affected by prazosin (1 microM). Furthermore, NPY was without effect on the dose-response curve to ATP in resting conditions. Taken together, these results suggest that in our paradigm, NPY inhibits the release of a purinergic neurotransmitter which mediates contraction of the prostatic portion of the rat vas deferens.

Adenosine Triphosphate↗
PubMed1995

Discrimination by benextramine between the NPY-Y1 receptor subtypes present in rabbit isolated vas deferens and saphenous vein.

1. In order to characterize the neuropeptide Y (NPY) Y1 receptors known to be present in rabbit isolated vas deferens and saphenous vein, the pharmacological activity of the selective NPY Y1 receptor agonists, [Leu31,Pro34] NPY and various other peptide agonists, together with the putative NPY antagonist, benextramine, were compared in the two tissues. 2. In rabbit isolated saphenous vein, cumulative dose-response curves to various NPY agonists were obtained. All the peptides tested caused contractions which developed quite slowly. The rank order of potency obtained was: PYY > NPY > [Leu31,Pro34] NPY = NPY2-36 > hPP >> NPY13-36 = NPY18-36. Incubation with benextramine (BXT) at 100 microM for 30 min irreversibly abolished the contractile response to [Leu31,Pro34] NPY but was ineffective against NPY18-36-induced contractions. 3. Cumulative dose-response curves to [Leu31,Pro34] NPY were performed in the same preparation before and after incubation with 100 microM BXT for 20 min in order to inactivate NPY Y1 receptors. The pKA (-logKA) estimation for [Leu31,Pro34] NPY was 7.60 +/- 0.30 using the operational model and 7.20 +/- 0.33 using the null method; the difference between the two methods was not statistically significant (P = 0.36). 4. Prostatic segments of rabbit vas deferens were electrically stimulated with single pulses. Immediately after stabilization of the contractile response, a cumulative dose-response curve to various NPY agonists was obtained in each tissue. The rank order of potency for twitch inhibition was: PYY> [Leu31,Pro34]NPY > NPY > hPP>NPY2- 36 >>NPY13-36>> NPY 18-36 which indicates the presence of a prejunctional NPY Y1 receptor. BXT at 100 microM incubated for 10 or 60 min did not antagonize the response to[Leu31,Pro34] NPY.5. We conclude that rabbit isolated saphenous vein contains a population of post-junctional NPY Y1 receptors irreversibly blocked by BXT, as well as a population of post-junctional NPY Y2 receptors,which are insensitive to BXT. In contrast, the rabbit isolated vas deferens express a pre-junctional NPYY1 receptor subtype which is not blocked by BXT. Tetramine disulphides such as BXT could be useful tools in classifying NPY receptors.

Animals↗
PubMed1995

Investigation of the actions of chloroethylclonidine in rat aorta.

1. The interaction between chloroethylclonidine (CEC) and noradrenaline (NA) has been examined at alpha-adrenoceptors mediating contractions of rat aorta. 2. In rat aorta, the competitive antagonist prazosin, over the concentration-range 0.01-10 microM, produced concentration-dependent shifts in the contractile potency of NA, so that there was no component of the NA contraction resistant to prazosin. 3. The irreversible alpha 1-adrenoceptor antagonists, phenoxybenzamine (PBZ) (1-10 microM) and benextramine (10 microM) produced shifts in potency of NA and reduced the maximum response in a concentration-dependent manner. 4. The irreversible alpha 1-adrenoceptor antagonist, CEC (100 microM), produced a non-parallel shift in the NA concentration-response curve so that low concentrations of NA produced relatively small contractions but relatively high concentrations produced further contractions, so that the maximum response was not significantly reduced. 5. The combination of CEC pretreatment and subsequent prazosin (0.1 microM) produced a parallel shift in the potency of NA. However, prazosin (10 microM) failed to produce any further effect on the response to high concentrations of NA following CEC pretreatment. Hence, a component of the contraction to NA in the presence of CEC was resistant to subsequent prazosin. Likewise, this component was resistant to a combination of prazosin (10 microM) and yohimbine (10 microM). 6. Receptor protection experiments were carried out in which tissues were exposed to NA (100 microM), yohimbine (10 microM) or prazosin (0.1 microM) prior to and during exposure to CEC. Receptor protection with NA, yohimbine or prazosin (0.1 microM), followed by washout prevented the shift in potency of NA produced by CEC. 7. Further experiments examined the effects of prazosin (10 microM) on responses to NA following receptor protection with NA (100 microM), yohimbine (10 microM), prazosin (10 microM), or xylazine (100 microM). In receptor protection studies with NA, subsequent prazosin (10 microM) produced a shift in response to NA following CEC which was not signficantly different from the shift produced by prazosin alone in the absence of receptor protection. In receptor protection studies with prazosin, yohimbine or xylazine, subsequent prazosin (10 microM) produced shifts in the response to NA following CEC which were significantly less than the shift produced by prazosin alone in the absence of receptor protection.8. It is concluded that CEC has two actions in the rat aorta. Firstly, it behaves as an irreversible a,-adrenoceptor antagonist, reducing the response to low concentrations of NA (up to 10 microM). However,after exposure to CEC, concentrations of NA of 10 microM and above produced contractions resistant toprazosin. This resistant component was still present following receptor protection with alpha1,- or alpha2-adrenoceptor antagonists, but absent following receptor protection with NA. Hence, the latter response may represent an irreversible agonist interaction between CEC, NA and alpha-adrenoceptors which cannot be affected by subsequent competitive antagonism, but which can be prevented by receptor protection with the agonist NA prior to CEC.

Adrenergic alpha-Antagonists↗
PubMed1984

The action and interaction of beta-phenethylamines and imidazolines on prejunctional alpha 2-adrenoceptors of guinea-pig ileum in the presence of the non-competitive antagonist benextramine.

The effects of benextramine, a selective non-competitive, irreversible antagonist of alpha-adrenoceptors, against alpha 2-adrenoceptor agonists has been investigated in isolated field-stimulated guinea-pig ileum. Benextramine was equipotent against the imidazoline, clonidine and the thiazoloazepine B-HT920, however, higher concentrations of benextramine were required for an equivalent non-competitive antagonism of the beta-phenethylamine, alpha-methylnoradrenaline. Using benextramine to differentially block the agonist effects of clonidine but not alpha-methylnoradrenaline it was shown that clonidine can competitively antagonize the effects of alpha-methylnoradrenaline. From these and previous results on the differential effects of imidazoline-like and beta-phenethylamine-like drugs on alpha 2-adrenoceptors, it is proposed that two distinct populations of these receptors exist.

Adrenergic alpha-Agonists↗
PubMed2005

Phenoxybenzamine and benextramine, but not 4-diphenylacetoxy-N-[2-chloroethyl]piperidine hydrochloride, display irreversible noncompetitive antagonism at G protein-coupled receptors.

Many irreversible antagonists have been shown to inactivate G protein-coupled receptors (GPCRs) and used to study agonists and spare receptors. Presumably, they bind to primary (agonist) binding sites on the GPCR, although noncompetitive mechanisms of antagonism have been demonstrated but not thoroughly investigated. We studied noncompetitive antagonism by phenoxybenzamine and benextramine at alpha(2A)-adrenoceptors in stably transfected Chinese hamster ovary cells, benextramine and 4-diphenylacetoxy-N-[2-chloroethyl]piperidine hydrochloride (4-DAMP mustard) at endogenous muscarinic acetylcholine (mACh) receptors in human neuroblastoma SH-SY5Y cells, and benextramine at serotonin 5-HT(2A) receptors in stably transfected SH-SY5Y cells. Primary binding sites were protected by reversible competitive antagonists during pretreatment with irreversible antagonists. We conducted appropriate radioligand binding assays by measuring remaining primary binding sites and agonist affinity, functional assays to evaluate agonist-induced responses, and constitutive guanosine 5'-O-(3-[(35)S]thio)triphosphate ([(35)S]GTPgammaS)-Galpha(o) binding assays to determine remaining G protein activity. Phenoxybenzamine (100 microM; 20 min) and benextramine (10 or 100 microM; 20 min) at alpha(2A)-adrenoceptors, but not 4-DAMP mustard (100 nM; 120 min) at mACh receptors, displayed irreversible noncompetitive antagonism in addition to their known irreversible competitive antagonism. Although agonist binding affinity is not influenced, signal transduction is modulated in a G protein-dependent manner via allotopic interactions. Benextramine noncompetitively inhibits agonist-induced responses at three different GPCR types (alpha(2A), mACh, and 5-HT(2A) receptors) that signal via three families of G proteins (G(i/o), G(s), and G(q/11)). We conclude that, where irreversible antagonists are utilized to study drug-receptor interaction mechanisms, the presence of significant irreversible noncompetitive antagonism may influence the interpretation of results under the experimental conditions used.

Adrenergic alpha-Agonists↗
PubMed1992

Further investigation of anticoccidial activity of 7-bromo-N-(2-imidazolidinylidene)-1H-indazol-6-amine.

The clonidine analog 7-bromo-N-(2-imidazolidinylidene)-1H-indazol-6-amine exhibits potent activity against Eimeria tenella infections in chickens. Disease control was abrogated by a selective alpha 2 antagonist, which is consistent with the dependence of such activity upon binding to receptors with characteristics of the vertebrate alpha 2 adrenoceptor. Lack of significant activity against the parasite in tissue culture and our inability to detect significant binding of alpha 2 adrenergic ligands to E. tenella imply that the anticoccidial action may be an indirect effect mediated by the host. Efficacy varied, depending upon the Eimeria species, being greatest for the cecal species E. tenella and less for the intestinal species. The effects described differ substantially from previous accounts of adrenergic actions on parasitic protozoa. The evidence suggests that we have observed a new mechanism of action for antiparasitic drugs.

Adrenergic alpha-Agonists↗
PubMed1979

Cardiac muscarinic blocking and atropinic blocking effects of a tetramine disulfide and alpha-adrenoceptor blocking activity.

Since many alpha-adrenoceptor blocking drugs were known to have muscarinic blocking activity, BHC, a newly synthesized tetramine disulfide with alpha-adrenoceptor blocking activity, and two of its analogs were tested for muscarinic blocking activity in the isolated guinea pig atrium and ileum. BHC had muscarinic blocking activity. Its potency was higher in the atrium than in the ileum. The cardiac muscarinic blocking potency of the analog that contained carbon atoms instead of sulfur atoms was similar to that of BHC. Lower concentrations of the drugs antagonized inotropic effects of acetylcholine competitively, but higher concentrations had a smaller effect than expected for competitive antagonism. In the atrium BHC competitively inhibited the muscarinic blocking effect of atropine. Its atropinic blocking potency was similar to the muscarinic blocking potency. Quinidine and gallamine also had muscarinic blocking and atropinic blocking effects in the atrium but were about 10 times less potent than BHC.

Adrenergic alpha-Antagonists↗
PubMed1980

Reactivation by cysteamine of vascular alpha adrenoceptors blocked by the tetramine disulfide benextramine and interaction of benextramine with phenoxybenzamine.

The tetramine disulfide benextramine irreversibly blocked the noradrenaline-induced contraction of the isolated rabbit aorta in a manner similar to that observed with phenoxybenzamine. Cysteamine abolished the benextramine blockade but not the phenoxybenzamine blockade. Incubation of aortic tissue with benextramine prior to phenoxybenzamine exposure and followed by cysteamine treatment led to a recovery of the noradrenaline response that depended on the dose of benextramine. Thus benextramine protected the alpha adrenoceptors against phenoxybenzamine blockade.

Animals↗
PubMed1984

Antagonism by the tetramine disulfide benextramine of the inhibitory effects mediated by prejunctional alpha 2-adrenoceptors and by postjunctional histamine H2 receptors in the mouse vas deferens.

The actions of benextramine, which blocks postjunctional alpha-adrenoceptors noncompetitively and irreversibly (non-equilibrium type) on prejunctional alpha-adrenoceptors (alpha 2) and postjunctional histamine H2 receptors, were studied in the mouse vas deferens, using clonidine and histamine, respectively, as the agonists. Both agonists caused a dose-related inhibition of the electrically evoked twitch responses, an inhibition that their respective antagonists (yohimbine or phentolamine, and cimetidine) antagonized competitively. Benextramine, however, antagonized the agonists' inhibitory effect noncompetitively. At the concentrations used, while clonidine or yohimbine and phentolamine protected the prejunctional alpha-adrenoceptors (alpha 2) against the benextramine noncompetitive blockade, histamine or cimetidine failed to protect the histamine H2 receptor against benextramine blockade. Therefore, although benextramine acts prejunctionally to block the alpha 2-adrenoceptors in the mouse vas deferens either by interacting directly with the same site as clonidine or yohimbine and phentolamine, or allosterically with a site close to it, it does not appear to act irreversibly, either directly or allosterically, with the same site as histamine or cimetidine. The mechanism by which benextramine blocks the histamine-induced inhibition of the electrically evoked twitch response in the mouse vas deferens remains to be established.

Adrenergic alpha-Antagonists↗
PubMed2005

A novel small molecule CFTR inhibitor attenuates HCO3- secretion and duodenal ulcer formation in rats.

The cystic fibrosis (CF) transmembrane conductance regulator (CFTR) plays a crucial role in mediating duodenal bicarbonate (HCO(3)(-)) secretion (DBS). Although impaired DBS is observed in CF mutant mice and in CF patients, which would predict increased ulcer susceptibility, duodenal injury is rarely observed in CF patients and is reduced in CF mutant mice. To explain this apparent paradox, we hypothesized that CFTR dysfunction increases cellular [HCO(3)(-)] and buffering power. To further test this hypothesis, we examined the effect of a novel, potent, and highly selective CFTR inhibitor, CFTR(inh)-172, on DBS and duodenal ulceration in rats. DBS was measured in situ using a standard loop perfusion model with a pH stat under isoflurane anesthesia. Duodenal ulcers were induced in rats by cysteamine with or without CFTR(inh)-172 pretreatment 1 h before cysteamine. Superfusion of CFTR(inh)-172 (0.1-10 microM) over the duodenal mucosa had no effect on basal DBS but at 10 microM inhibited acid-induced DBS, suggesting that its effect was limited to CFTR activation. Acid-induced DBS was abolished at 1 and 3 h and was reduced 24 h after treatment with CFTR(inh)-172, although basal DBS was increased at 24 h. CFTR(inh)-172 treatment had no effect on gastric acid or HCO(3)(-) secretion. Duodenal ulcers were observed 24 h after cysteamine treatment but were reduced in CFTR(inh)-172-pretreated rats. CFTR(inh)-172 acutely produces CFTR dysfunction in rodents for up to 24 h. CFTR inhibition reduces acid-induced DBS but also prevents duodenal ulcer formation, supporting our hypothesis that intracellular HCO(3)(-) may be an important protective mechanism for duodenal epithelial cells.

Animals↗
PubMed1994

Effects of maturation on alpha-adrenergic receptor affinity and occupancy in small cerebral arteries.

The present experiments examine the hypothesis that changes in receptor affinity and occupation mediate maturational changes in norepinephrine sensitivity in small cerebral arteries. In second-order (2B) and fourth-order (4B) branch middle cerebral artery segments from newborn and adult sheep, we first found that a stretch ratio based on artery diameter better estimated optimal prestretch than did passive tension. Next, we determined norepinephrine dose-response relations before and after prazosin, yohimbine, and benextramine. Prazosin competitively blocked contractions to norepinephrine, but yohimbine had no effect, indicating that alpha 1-adrenoceptors mediated contraction. Norepinephrine sensitivity [determined from the -log of the half-maximal effective dose (pD2)], maximal response, and binding affinity all decreased with age in 4B but not 2B segments. Receptor occupancy at the pD2 increased with age only in 2B segments. In conclusion, maturation of ovine middle cerebral arteries involves branch-specific changes in affinity and receptor occupation of the alpha 1-adrenoceptors that mediate contractile responses to norepinephrine. Age-related changes in receptor density and/or intrinsic efficacy probably are involved also.

Adrenergic alpha-Antagonists↗
PubMed1990

Norepinephrine and neuropeptide Y: vasoconstrictor cooperation in vivo and in vitro.

Norepinephrine (NE)-evoked vasoconstrictor and pressor responses are reduced after prolonged exposure; such desensitization is observed both clinically and experimentally. The vasoconstrictor neuropeptide Y (NPY) coexists with NE in perivascular sympathetic nerves, and the results of both in vivo and in vitro studies have indicated functional cooperation between NE and NPY. We propose that NPY becomes increasingly important in situations of high sympathetic activity associated with blunted NE responses. Prolonged NE infusion in conscious rats resulted in adrenergic desensitization; however, NPY administration restored the responsiveness to NE. In naive rats, NE greatly enhanced the pressor action of NPY. An analogous phenomenon was observed in the rabbit isolated pulmonary artery, which failed to respond to NPY unless preexposed to NE; this action of NE was only partly inhibited by conventional adrenoceptor and Ca2+ influx blockade. Conversely, NPY enhanced NE-evoked constriction, in particular when the alpha-adrenoceptor reserve was eliminated. It is proposed that threshold synergism, in part caused by converging stimulation of phospholipase C, accounts for much of the NPY/NE cooperativity. We conclude that 1) NPY and NE cooperate to produce vasoconstriction, both in vivo and in vitro; 2) NPY has the capacity to reverse adrenergic desensitization but not vice versa; 3) NE enhances NPY-evoked vasoconstriction, in part independently of conventional adrenoceptor blockade; 4) threshold synergism phenomena, but not "receptor-receptor interactions," account for (most of) the observed NPY/NE cooperation; and 5) when present, alpha-adrenoceptor reserve prevents the lowering of the NE threshold by NPY.

Adrenergic alpha-Agonists↗
PubMed1987

Transglutaminase activity and embryonal carcinoma cell differentiation.

Murine embryonal carcinoma (EC) cells induced to differentiate by retinoic acid (RA) modulate transglutaminase (TGase) activity shortly after exposure to the inducer. Compounds that inhibit TGase enzyme activity in vitro can successfully block RA induced EC cell differentiation in culture. These observations suggest that TGase may play a role in mediating RA induced EC cell differentiation.

Animals↗